Patent classifications
G01N33/545
ANTI-HUMAN IGG4 MONOCLONAL ANTIBODY AND HUMAN IGG4 ASSAY REAGENT USING SAID ANTIBODY
Provided are: a monoclonal antibody against human IgG4, for which the epitope is present in the CH3 of human IgG4 given by SEQ ID NO: 4; a hybridoma that produces the monoclonal antibody; a method for detecting IgG4 using the monoclonal antibody; and a kit used in this method.
ANTI-HUMAN IGG4 MONOCLONAL ANTIBODY AND HUMAN IGG4 ASSAY REAGENT USING SAID ANTIBODY
Provided are: a monoclonal antibody against human IgG4, for which the epitope is present in the CH3 of human IgG4 given by SEQ ID NO: 4; a hybridoma that produces the monoclonal antibody; a method for detecting IgG4 using the monoclonal antibody; and a kit used in this method.
METHOD FOR DIAGNOSING CANINE PREGNANCY AND DIAGNOSTIC REAGENT THEREFOR
It is an object of the present invention to provide a method for diagnosing canine pregnancy and a diagnostic reagent therefor. Specifically, the present invention relates to a method for diagnosing canine pregnancy, comprising a step of immunologically measuring a canine acute phase protein in a biological sample using an anti-canine acute phase protein antibody or a fragment thereof, wherein the canine acute phase protein is not a canine C-reactive protein.
METHOD FOR DIAGNOSING CANINE PREGNANCY AND DIAGNOSTIC REAGENT THEREFOR
It is an object of the present invention to provide a method for diagnosing canine pregnancy and a diagnostic reagent therefor. Specifically, the present invention relates to a method for diagnosing canine pregnancy, comprising a step of immunologically measuring a canine acute phase protein in a biological sample using an anti-canine acute phase protein antibody or a fragment thereof, wherein the canine acute phase protein is not a canine C-reactive protein.
Methods for diagnosis and prognosis of renal injury and renal failure using insulin-like growth factor-binding protein 7 and metalloproteinase inhibitor 2
The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in sepsis patients. In particular, the invention relates to using assays that detect one or more biomarkers selected from the group consisting of Insulin-like growth factor-binding protein 7, Beta-2-glycoprotein 1, Metalloproteinase inhibitor 2, Alpha-1 Antitrypsin, Leukocyte elastase, Serum Amyloid P Component, C-X-C motif chemokine 6, Immunoglobulin A, Immunoglobulin G subclass I, C-C motif chemokine 24, Neutrophil collagenase, Cathepsin D, C-X-C motif chemokine 13, Involucrin, Interleukin-6 receptor subunit beta, Hepatocyte Growth Factor, CXCL-1, -2, -3, Immunoglobulin G subclass II, Metalloproteinase inhibitor 4, C-C motif chemokine 18, Matrilysin, C-X-C motif chemokine 11, and Antileukoproteinase as diagnostic and prognostic biomarker assays of renal injury in the sepsis patient.
Methods for diagnosis and prognosis of renal injury and renal failure using insulin-like growth factor-binding protein 7 and metalloproteinase inhibitor 2
The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in sepsis patients. In particular, the invention relates to using assays that detect one or more biomarkers selected from the group consisting of Insulin-like growth factor-binding protein 7, Beta-2-glycoprotein 1, Metalloproteinase inhibitor 2, Alpha-1 Antitrypsin, Leukocyte elastase, Serum Amyloid P Component, C-X-C motif chemokine 6, Immunoglobulin A, Immunoglobulin G subclass I, C-C motif chemokine 24, Neutrophil collagenase, Cathepsin D, C-X-C motif chemokine 13, Involucrin, Interleukin-6 receptor subunit beta, Hepatocyte Growth Factor, CXCL-1, -2, -3, Immunoglobulin G subclass II, Metalloproteinase inhibitor 4, C-C motif chemokine 18, Matrilysin, C-X-C motif chemokine 11, and Antileukoproteinase as diagnostic and prognostic biomarker assays of renal injury in the sepsis patient.
METAL COMPLEX PARTICLES AND IMMUNOASSAY REAGENT USING SAME
Metal complex particle including a magnetic material and a particle size adjusting composition containing a hydrophobic polymer, with the magnetic material including a metal complex consisting of a metal ion and a ligand and having both magnetism and fluorescence, and a content of the particle size adjusting composition in the metal complex particle being less than 60 w %.
METAL COMPLEX PARTICLES AND IMMUNOASSAY REAGENT USING SAME
Metal complex particle including a magnetic material and a particle size adjusting composition containing a hydrophobic polymer, with the magnetic material including a metal complex consisting of a metal ion and a ligand and having both magnetism and fluorescence, and a content of the particle size adjusting composition in the metal complex particle being less than 60 w %.
PARTICLE, AFFINITY PARTICLE, AND REAGENT, KIT AND DETECTION METHOD CONTAINING THE SAME
The present invention provides a particle that shows a small non-specific adsorption, has a reactive functional group for chemically bonding a ligand thereto, and is suitable for an agglutination method. The particle includes a polymer having a unit having a side chain A and a unit having a side chain B, wherein the side chain A has a carboxyl group at a terminal thereof, and has an ester bond and an amide bond in a molecular structure thereof; the side chain B has an alkyl group at a terminal thereof; and a zeta potential at the time when the particles are dispersed in water is minus 40 mV or higher and minus 5 mV or lower.
PARTICLE, AFFINITY PARTICLE, AND REAGENT, KIT AND DETECTION METHOD CONTAINING THE SAME
The present invention provides a particle that shows a small non-specific adsorption, has a reactive functional group for chemically bonding a ligand thereto, and is suitable for an agglutination method. The particle includes a polymer having a unit having a side chain A and a unit having a side chain B, wherein the side chain A has a carboxyl group at a terminal thereof, and has an ester bond and an amide bond in a molecular structure thereof; the side chain B has an alkyl group at a terminal thereof; and a zeta potential at the time when the particles are dispersed in water is minus 40 mV or higher and minus 5 mV or lower.